[Effect of Astragalus membranaceus injection on megakaryocyte hematopoiesis in anemic mice]
Related Experiment Video
Updated: Sep 27, 2026
Isolation and Intravenous Injection of Murine Bone Marrow Derived Monocytes
Published on: December 27, 2014
1Department of Histology and Embryology, School of Basic Medical Sciences, WCUMS, Chengdu 610041, China.
Objective:
To assess the effect of Astragalus membranaceus injection (AMI) on megakaryocyte hematopoiesis in anemic mice and explore its mechanism.
Methods:
Anemic models of mice were randomly divided into two groups: treatment group and anemic control group. Intraperitoneal doses of AMI (20 mg/(ml.20 g) q.d x 6) were given to the treatment group, and equal doses of physiological saline were given to the anemic control group. On days 8, 11 and 14 after treatment, blood platelet and bone marrow cells were determined, and the numbers of CFU-Meg (colony forming unit-megakaryocyte) and Meg-CSA (megakaryocyte colony-stimulating activity) were determined by using technique of hematopoietic progenitor cells culture in vitro.
Results:
Serum Meg-CSA of the treatment group was significantly higher than that of the anemic control group. The abovementioned indices of the treatment group recovered to normal by day 11, which was markedly earlier than the day of recovery observed in the anemic control group.
Conclusion:
AMI can increase serum Meg-CSA of anemic mice and accelerate the recovery of megekaryocyte hematopoiesis after bone marrow suppression.
Insights
Astragalus membranaceus injection (AMI) significantly boosted megakaryocyte hematopoiesis in anemic mice. AMI accelerated the recovery of platelet production and bone marrow cell counts, demonstrating its therapeutic potential.
Area of Science:
- Hematology
- Pharmacology
- Traditional Chinese Medicine
Background:
- Anemia and bone marrow suppression can lead to impaired platelet production.
- Megakaryocyte hematopoiesis is crucial for maintaining adequate platelet levels.
- Exploring novel therapeutic agents for hematological recovery is essential.
Purpose of the Study:
- To evaluate the efficacy of Astragalus membranaceus injection (AMI) in promoting megakaryocyte hematopoiesis.
- To investigate the underlying mechanisms of AMI's action in anemic mice.
- To assess AMI's impact on recovery from bone marrow suppression.
Main Methods:
- Anemia models were established in mice and divided into treatment (AMI) and control (saline) groups.
- Mice received daily intraperitoneal injections of AMI or saline for six days.
- Hematological parameters, including platelet counts, bone marrow cells, and in vitro hematopoietic progenitor cell cultures (CFU-Meg, Meg-CSA), were assessed.
Main Results:
- Astragalus membranaceus injection (AMI) significantly increased serum megakaryocyte colony-stimulating activity (Meg-CSA) in anemic mice.
- Key hematological indices in the AMI-treated group recovered to normal levels by day 11.
- Recovery was markedly accelerated compared to the anemic control group.
Conclusions:
- Astragalus membranaceus injection (AMI) effectively enhances serum Meg-CSA in anemic mice.
- AMI accelerates the recovery of megakaryocyte hematopoiesis following bone marrow suppression.
- These findings suggest AMI as a potential therapeutic agent for hematological disorders.
